Zura Bio (NASDAQ:ZURA) Given “Buy” Rating at Guggenheim

Zura Bio (NASDAQ:ZURA)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $15.00 price target on the stock.

A number of other equities analysts also recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Chardan Capital decreased their target price on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.33.

Zura Bio Stock Down 7.7 %

ZURA stock opened at $1.38 on Wednesday. The company has a fifty day moving average price of $1.49 and a 200-day moving average price of $2.77. Zura Bio has a 52-week low of $1.07 and a 52-week high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. On average, equities research analysts anticipate that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Institutional Trading of Zura Bio

Large investors have recently modified their holdings of the stock. Two Sigma Advisers LP acquired a new stake in Zura Bio in the fourth quarter worth $32,000. Shay Capital LLC acquired a new stake in shares of Zura Bio in the 4th quarter valued at about $233,000. ProShare Advisors LLC acquired a new stake in shares of Zura Bio in the 4th quarter valued at about $35,000. Millennium Management LLC increased its position in Zura Bio by 1,499.0% in the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after buying an additional 657,420 shares in the last quarter. Finally, Forefront Analytics LLC raised its stake in Zura Bio by 74.4% during the 4th quarter. Forefront Analytics LLC now owns 53,734 shares of the company’s stock worth $134,000 after buying an additional 22,924 shares during the period. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.